eContinence: The company behind the Tät® app
Millions of people all over the world restrict how they live their lives due to urinary leakage. Our team is driven by the desire to make simple and effective treatment available to everybody, regardless of where you live.
Founded in 2021, the med-tech company eContinence AB was created by a team of doctors and researchers who had worked together in the research project Tät.nu at Umeå University in Sweden. The purpose of this research project was to develop, evaluate and implement an e-health application for the treatment of urinary incontinence. The Tät app was the first incontinence treatment app in the world to be scientifically evaluated in clinical trials, and it has received great attention from the incontinence research community internationally. Research regarding the Tät® app is now complete, and the eContinence team is now managing and building on our work so that the app continues to be available and to develop. Feel free to contact us.
Eva Samuelsson
CEO of eContinence AB
Professor and specialist in Family Medicine
Emma Nyström
Dr. Med and Resident physician of Family Medicine
Ina Asklund
Dr. Med and specialist in Family Medicine
Malin Sjöström
Associate professor and specialist in Family Medicine
Fredrik Jonsson
Head of Sales and Business Development/QA
Important milestones
2024
- We released a completely new version of Tät® on a new technical platform with a new look, simpler navigation, and more features.
- We started a collaboration with the Swedish Prostate Cancer Foundation concerning the Tät app for men.
2023
- The Tät® app is released in a new version with new functions. The app is used by many women for pelvic floor muscle training during pregnancy and after childbirth. This is supported by research.
2022
- The award ”Innovation Champions of the year”, Region Jämtland Härjedalen goes to our team.
- New content and features make the Tät® app even better. It is released as a free version and as a Premium version. It is intended to treat urinary leakage triggered by exertion.
- Granted support from Vinnova (MedTech4Health)
- Regional innovation support from Region JH
- Winner of Umeå University’s/Nordea’s innovation award for creating value from research (Eva Samuelsson).
2021
- Umeå Universitet Holding invests in eContinence AB
- Winner of Sigrid Strand’s award for female innovators (Eva Samuelsson).
- The company is accepted into the Uminova innovation incubator in Umeå.
- eContinence AB, Östersund is registered in July 2021.
- The Tät® app is CE-marked as a class I medical device, under MDR 2017/745.
- The Tät® app is audited and recommended by SALAR (Swedish Association of Local Authorities and Regions).
2018-2021
- The project participates in the verification program that Umeå University offers to researchers via its Innovation Office, with continuous support from innovation advisors and business coaches.
2020
- The Tät® app is recommended by Nikola (a network for bladder and intestinal dysfunction in Sweden)
- The Tät® app is recommended by healthcare centres, maternity departments and clinics all over Sweden.
2008-2022
- Three doctoral theses and 21 scientific articles have been published within the research project, financed through national, regional and local fundings. One internet programme and three apps have been developed and evaluated within the project.
2015
- The trademark Tät is registered.
2008
- The research project Tät.nu at Umeå University, Sweden, is founded by Eva Samuelsson and Göran Umefjord. The aim is to develop, evaluate and implement e-health for treatment of urinary incontinence.
With funding from:
